ClinicalTrials.gg
CompletedNCT02165826OPTIMIZEUpdated Apr 20, 2017Results posted

Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD

A Phase 3 interventional study of Roflumilast and Roflumilast Placebo in Chronic Obstructive Pulmonary Disease (COPD), sponsored by AstraZeneca. Completed at 2 sites in Slovakia. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2017-04-20.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,323
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive — 1 open to participants now, 1 under way, none of them phase 3. Roflumilast · Pulmonary Disease, Chronic Obstructive.

Enrollment
5th of 32
1,323 · median 154
Started
2014
with 1 other
Phase 3
16 of 32
none open now
Registered
26th of 32
by date
Lead sponsor
18 of 32
AstraZeneca

Among the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, this one is the 5th largest by enrollment, is one of 2 that started in 2014, is one of 16 in phase 3, and was the 26th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

1 of the 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive is open now. Recruiting first, the newest first:

About roflumilast

Roflumilast: first FDA approval 2011 (DALIRESP), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing roflumilast in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate discontinuation rates of roflumilast using an up-titration regimen for the first 4 weeks of treatment compared with continuous treatment of 500 μg one daily (OD) during the entire 12-week main period, and to evaluate if participants who do not tolerate roflumilast 500 μg OD have a drug exposure with 250 μg roflumilast OD similar to that observed in other participants with the 500 μg OD dose.

Read the detailed description

Roflumilast is a product which has been approved for the treatment of severe chronic obstructive lung disease (COPD) and its approved dose is 500μg once daily. This study is primarily designed to see whether alternation in this dose can improve tolerability of Roflumilast in COPD patients. Therefore one in three patients will start roflumilast therapy at a lower dose of 250μg once daily, another one in three will only take the 500μg tablet every other day (and one placebo every other day). Rest of them will start the regular dose of 500μg once daily right away and see whether starting with a lower dose of Roflumilast will lead to better tolerability. Furthermore, the study will see if patients who do not tolerate roflumilast should be given a lower dose of 250μg once daily.

Lastly, the study will investigate what the body does to roflumilast. Patients with a history of COPD for at least last 12 months and a former smoker or current smoker with history of at least 10 pack years will be invited to participate.

The main study period lasts for a maximum of 15 weeks and patients will have to visit the study site up to 6 times. If patients are not tolerating roflumilast, the investigators may switch them to the down titration period where they may be on a lower dose for rest of the study. Then patients will remain in the down titration period for additional 8 weeks and will have to visit the study site 4 times. Most of the visits will take approximately 1 to 2 hours. However, one visit in the main period and 1 or 2 visits in the down titration period will take approximately 6 to 7 hours. These visits are longer to allow time to conduct blood taking.

The Randomization visit is considered the Baseline visit and for participants that discontinue the Main Period and continue into the Down-Titration Period Day 1 of Down Titration is considered BaselineDT.

03

Conditions studied

  • Chronic Obstructive Pulmonary Disease (COPD)

Keywords

  • Drug therapy
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. In the opinion of the investigator, the participant is capable of understanding and complying with protocol requirements.
  2. The participant or, when applicable, the participant's legally acceptable representative signs and dates a written, form and any required privacy authorization prior to the initiation of any study procedures.
  3. Has a history of (COPD) (according to Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013) for at least 12 months prior to Screening (Visit V0) associated with chronic productive cough for 3 months in each of the 2 years prior to Screening (Visit V0, with other causes of productive cough excluded).
  4. Shows a post-bronchodilator (FEV1) of ≤50% of predicted.
  5. Shows an FEV1/forced vital capacity (FVC) ratio (post-bronchodilator) \<70%.
  6. Has at least one documented COPD exacerbation within one year prior to Screening (Visit V0).
  7. Is on standard of care COPD maintenance treatment including Long Acting β2-Agonist (LABAs), long-acting anticholinergics, or any combination thereof taken on a constant daily dose within 12 weeks prior to Screening (Visit V0).
  8. Must be a former smoker (defined as smoking cessation at least one year ago) or current smoker both with a smoking history of at least 10 pack years.11
  9. Is male or female and aged 40 or older.
  10. A female participant of who is sexually active with a nonsterilized male partner agrees to use routinely adequate from signing of informed consent throughout the duration of the study.

Exclusion criteria

Exclusion Criteria:

Criteria affecting the read-out parameters of the study

  1. Has a exacerbation ongoing at the Screening (Visit V0), or has a COPD exacerbation between V0 and V1.
  2. Has a lower respiratory tract infection not resolved 4 weeks prior to Screening (Visit V0).
  3. Has a diagnosis of asthma and/or other relevant lung disease (eg, history of primary bronchiectases, cystic fibrosis, bronchiolitis, lung resection, lung cancer, interstitial lung disease [eg, fibrosis, silicosis, sarcoidosis], or active tuberculosis).
  4. Has a known α1-antitrypsin deficiency.
  5. Has taken roflumilast within 6 months of Screening (Visit V0).

    Criteria within ethical considerations in terms of general health

  6. Has abnormal laboratory values suggesting an undiagnosed disease requiring further clinical evaluation (as assessed by the investigator).
  7. Has a history of severe psychiatric or neurological disorders.
  8. Has a history of depression associated with suicidal ideation or behavior.
  9. Has congestive heart failure severity grade IV according to (NYHA) Functional Classification.
  10. Has hemodynamically significant cardiac arrhythmias or heart valve deformations.
  11. Has computed tomography (CT) or chest x-ray findings indicating an acute pulmonary disease other than COPD (eg, tuberculosis, severe bronchiectasis, tumors).
  12. Has severe immunological diseases (eg, known human immune deficiency virus () infection, multiple sclerosis, lupus erythematosus, progressive multifocal leukoencephalopathy).
  13. Has liver impairment B or C and/or active viral hepatitis.
  14. Has severe acute infectious diseases (eg, tuberculosis, or acute hepatitis).
  15. Has a history of malignant disease (except basal cell carcinoma) within 5 years before Screening (Visit V0).
  16. Has a history of drug abuse (defined as any illicit drug use) or a history of alcohol abuse within one year before Screening (Visit V0).
  17. Has a history of or allergies to roflumilast or rescue medication or ingredients thereof, or any other for the use thereof.
  18. If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 12 weeks after participating in this study; or intending to donate ova during such time period.
  19. Intends to donate blood, organs, or bone marrow during the course of the study.
  20. Has received any compound within 30 days prior to Screening (Visit V0), is currently participating in another interventional clinical study, or has been previously enrolled in this study.
  21. Is suspected to be unable or unwilling to comply with study procedures (eg, language problems, psychological disorders, number and timing of visits at the center).
  22. Suffers from any concomitant disease that might interfere with study procedures or evaluations.
  23. Is required to take excluded medications.
  24. Is an immediate family member, study center employee, or is in a dependent relationship with a study site employee who is involved in conduct of this study (eg, spouse, parent, child, sibling), or may consent under duress.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,323 participants (actual)

Study arms

  • Experimental
    Roflumilast 500 μg once daily

    Roflumilast 500 μg tablets, orally, once daily for 12 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.

    Drug: Roflumilast · Drug: Standard of Care COPD Treatment

  • Experimental
    Roflumilast 500 μg every other day

    Roflumilast 500 μg, tablets, orally, every other day, and roflumilast placebo-matching tablets, orally, every other day on non-treatment days, for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.

    Drug: Roflumilast · Drug: Roflumilast Placebo · Drug: Standard of Care COPD Treatment

  • Experimental
    Roflumilast 250 μg once daily

    Roflumilast 250 μg, tablets, orally, once daily for 4 weeks, followed by roflumilast 500 μg, tablets, orally, once daily, for 8 weeks. Any participants not tolerating study treatment will be prematurely discontinued and will receive roflumilast 250 μg, tablets, orally, once daily for 8 weeks.

    Drug: Roflumilast · Drug: Standard of Care COPD Treatment

Interventions

  • Roflumilast tablets

    Also known as: Daxas, Daliresp, Libertek

  • DrugRoflumilast Placebo

    Roflumilast placebo-matching tablets

  • DrugStandard of Care COPD Treatment

    The participant is on standard of care COPD maintenance treatment including LABAs, long-acting anticholinergics, or any combination thereof taken on a constant daily dose within 12 weeks prior to Screening (Visit V0) Examples of LABA containing products are: Formoterol, Salmeterol, Indacaterol, Formoterol/Budesonide, Salmeterol/Fluticasone, Treatment including lon-acting anticholinergics: Tiotropium, Aclidinium.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Prematurely Discontinuing Study Treatment Due to Any Reason

    The primary endpoint is the percentage of participants prematurely discontinuing study treatment for any reason during the Main Period from Visit 1 (V1) to Last Visit (Vend). Discontinuation is defined as permanently stopping randomized treatment; participants who resume randomized treatment after an interval will not be counted as having discontinued. The analysis used discontinuations occurring during the Main Period, irrespective of whether a participant subsequently entered into the Down-Titration Period.

    Time frame: Baseline to Week 12 (Main Period)

Secondary outcomes

  1. Percentage of Participants With Adverse Events of Interest

    Adverse events of interest to evaluate tolerability are defined as diarrhea, nausea, headache, decreased appetite, insomnia and abdominal pain.

    Time frame: Baseline to Week 12 (Main Period)

  2. Change From Baseline (V0DT) in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) to Final Visit of the Down-Titration Period

    FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication A positive change from Baseline indicates improvement.

    Time frame: Baseline (V0DT) [assessment at end of main period] and Final Visit of Down-Titration Period (Up to Day 56)

  3. Percentage of Participants Prematurely Discontinuing Study Treatment Due to Any Reason During Down-Titration Period

    Time frame: Baseline DT (Day 1 of Down-Titration Period) to Week 8 (Down-Titration Period)

  4. Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) During the Down-Titration Period

    FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.

    Time frame: Baseline DT (Day 1 of Down-Titration Period) to Days 14, 28 and 56 (Down-Titration Period)

  5. Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) During the Main Period

    FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.

    Time frame: Baseline (Day 1 of Main Period) to Days 15, 29, 57 and 84 (Main Period)

  6. Change From Baseline in Pre-bronchodilator Forced Vital Capacity (FVC) During the Main Period

    Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.

    Time frame: Baseline (Day 1 of Main Period) to Days 15, 29, 57 and 84 (Main Period)

  7. Change From Baseline in Pre-bronchodilator Forced Vital Capacity (FVC) During the Down-Titration Period

    Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.

    Time frame: Baseline DT (Day 1 of Down-Titration Period) to Days 14, 28 and 56 (Down-Titration Period)

  8. Change From Baseline in Treatment Satisfaction Scores During the Main Period

    Participants will be asked to assess their satisfaction with their COPD therapy at each visit. The participants will rate their treatment satisfaction on a 7-point scale where 0=very satisfied, 1=satisfied, 2=somewhat satisfied, 3=neither satisfied nor dissatisfied, 4=somewhat dissatisfied, 5=dissatisfied and 6=very dissatisfied. A negative change from Baseline indicates improvement.

    Time frame: Baseline (Day 1 of Main Period) to Days 15, 29, 57 and 84 (Main Period)

  9. Change From Baseline in Treatment Satisfaction Scores During the Down-Titration Period

    Participants will be asked to assess their satisfaction with their COPD therapy at each visit. The participants will rate their treatment satisfaction on a 7-point scale where 0=very satisfied, 1=satisfied, 2=somewhat satisfied, 3=neither satisfied nor dissatisfied, 4=somewhat dissatisfied, 5=dissatisfied and 6=very dissatisfied. A negative change from Baseline indicates improvement.

    Time frame: Baseline DT (Day 1 of Down-Titration Period) to Days 14, 28 and 56 (Down-Titration Period)

  10. Population PK Model Point Estimate for Absorption Rate Constant (Ka) of Roflumilast and Roflumilast N-oxide

    PK model point estimates for Ka are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.

    Time frame: Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours at weeks 2 or 8

  11. Population PK Model Point Estimate for Apparent Oral Clearance (CL/F) of Roflumilast and Roflumilast N-oxide

    PK model point estimates for CL/F are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.

    Time frame: Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours at weeks 2 or 8

  12. Population PK Model Point Estimate for Apparent Central Volume (Vc/F) of Roflumilast and Roflumilast N-oxide

    PK model point estimates for Vc/F are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.

    Time frame: Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours at weeks 2 or 8

  13. Population PK Model Point Estimate for Apparent Peripheral Volume (Vp/F) of Roflumilast and Roflumilast N-oxide

    PK model point estimates for Vp/F are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.

    Time frame: Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours at weeks 2 or 8

  14. Total PDE4 Inhibitory Activity (tPDE4i)

    tPDE4i was derived using in-vitro constants for protein binding and biochemical activity (IC50). tPDE4i is reported for a set of reference participants defined according to the covariates included in the final model.

    Time frame: Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours post-dose at Days 15 and 57. Down-titration: Pre-dose and 1,2,3,4,6 hours post-dose at Days 1 and 14 and pre-dose at Days 28 and 56.

  15. Summary Statistics of Predicted Total PDE4 Inhibitory Activity (tPDE4i)

    tPDE4i was derived using in-vitro constants for protein binding and biochemical activity (IC50). An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. Adverse Events of Interest (AEI) for PK analyses included: headache, diarrhea, nausea, vomiting, abdominal pain, appetite disorders, sleep disorders, angioedema, psychiatric disorders (anxiety, nervousness), psychiatric disorders (depression,suicidal ideation,behaviour) and weight loss.

    Time frame: Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours post-dose at Days 15 and 57. Down-titration: Pre-dose and 1,2,3,4,6 hours post-dose at Days 1 and 14 and pre-dose at Days 28 and 56.

  16. Median Simulated Percentage of Participants With Adverse Events of Interest

    The PK model predicted the total PDE4 inhibitory activity and the median simulated percentage of participants with Adverse Events of Interest during 12 weeks of treatment based on 1000 participants simulated. Results are reported for the set of reference participants defined according to the covariates \[weight, smoking status, sex, age and long acting muscarinic antagonist (LAMA)\] included in the final model and tPDE4i. Adverse Events of Interest (AEI) for PK analyses included: headache, diarrhea, nausea, vomiting, abdominal pain, appetite disorders, sleep disorders, angioedema, psychiatric disorders (anxiety, nervousness), psychiatric disorders (depression, suicidal ideation, behaviour) and weight loss.

    Time frame: Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours post-dose at Days 15 and 57. AEIs: 12 Weeks

  17. Median Simulated Absolute Change From Baseline in FEV1 at Weeks 4 and 12

    The PK model predicted the total PDE4 inhibitory activity and the median simulated Change from Baseline (CFB) in FEV1 at Week 4 and the Change from Baseline in FEV1 at Week 12 during 12 weeks of treatment with roflumilast 500 μg OD based on 1000 participants simulated. Results are reported for the set of reference participants defined according to the covariates \[weight, smoking status, sex, age, race, COPD severity, concomitant long acting muscarinic antagonist (LAMA) and Percent FEV1 reversibility\] included in the final model and tPDE4i. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.

    Time frame: Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours post-dose at Days 15 and 57. FEV-1: Pre-dose and Weeks 4 and 12

07

Results

Posted Mar 14, 2017

Participant flow

Participants took part in the study at 161 investigative sites in Bulgaria, Germany, Greece, Hungary, Korea, Philippines, Poland, Romania, Russia, Slovakia, South Africa, Spain, Thailand, Ukraine and the United Kingdom from 30 April 2014 to 21 October 2015.

Main Treatment Period
Participant flow — Main Treatment Period
MilestoneRoflumilast 250 μg OD Then 500 μg ODRoflumilast 500 μg EOD Then 500 μg ODRoflumilast 500 μg OD
Started441439443
Safety analysis set: received study drug441437443
Completed360349334
Not completed8190109
Withdrew: Pre-treatment event/adverse event445768
Withdrew: Major/significant protocol deviation013
Withdrew: Lost to follow-up421
Withdrew: Voluntary withdrawal232321
Withdrew: Lack of efficacy200
Withdrew: Reason not specified8516
Withdrew: Did not receive study drug020
Down-Titration Period
Participant flow — Down-Titration Period
MilestoneRoflumilast 250 μg OD Then 500 μg ODRoflumilast 500 μg EOD Then 500 μg ODRoflumilast 500 μg OD
Started273938
Safety analysis set: received study drug273938
Completed202831
Not completed7117
Withdrew: Pre-treatment event/adverse event4103
Withdrew: Voluntary withdrawal212
Withdrew: Reason not specified102

Outcome measures

PrimaryPercentage of Participants Prematurely Discontinuing Study Treatment Due to Any Reason

The primary endpoint is the percentage of participants prematurely discontinuing study treatment for any reason during the Main Period from Visit 1 (V1) to Last Visit (Vend). Discontinuation is defined as permanently stopping randomized treatment; participants who resume randomized treatment after an interval will not be counted as having discontinued. The analysis used discontinuations occurring during the Main Period, irrespective of whether a participant subsequently entered into the Down-Titration Period.

Time frame:
Baseline to Week 12 (Main Period)
Reported as:
Number · percentage of participants
Percentage of Participants Prematurely Discontinuing Study Treatment Due to Any Reason
percentage of participantsRoflumilast 250 μg OD Then 500 μg ODRoflumilast 500 μg EOD Then 500 μg ODRoflumilast 500 μg OD
Percentage of Participants Prematurely Discontinuing Study Treatment Due to Any Reason18.420.124.6
Statistical analysis
  • Roflumilast 250 μg OD Then 500 μg OD vs Roflumilast 500 μg OD · Regression, Logistic · p = 0.017 (Study treatment, country and baseline forced expiratory volume in the first second (FEV1) as explanatory variables.) · Odds ratio (or): 0.66 · 95% CI 0.47 to 0.93
  • Roflumilast 250 μg OD Then 500 μg OD vs Roflumilast 500 μg OD · Cox proportional hazard: 0.68 · 95% CI 0.51 to 0.92Cox proportional hazards model with study treatment and country as class effects, and baseline FEV1 as a continuous variable.
  • Roflumilast 500 μg EOD Then 500 μg OD vs Roflumilast 500 μg OD · Regression, Logistic · p = 0.114 (Study treatment, country and baseline forced expiratory volume in the first second (FEV1) as explanatory variables.) · Odds ratio (or): 0.76 · 95% CI 0.55 to 1.07
  • Roflumilast 500 μg EOD Then 500 μg OD vs Roflumilast 500 μg OD · Cox proportional hazard: 0.77 · 95% CI 0.58 to 1.02Cox proportional hazards model with study treatment and country as class effects, and baseline FEV1 as a continuous variable.
SecondaryPercentage of Participants With Adverse Events of Interest

Adverse events of interest to evaluate tolerability are defined as diarrhea, nausea, headache, decreased appetite, insomnia and abdominal pain.

Time frame:
Baseline to Week 12 (Main Period)
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events of Interest
percentage of participantsRoflumilast 250 μg OD Then 500 μg ODRoflumilast 500 μg EOD Then 500 μg ODRoflumilast 500 μg OD
Percentage of Participants With Adverse Events of Interest45.448.354.2
Statistical analysis
  • Roflumilast 250 μg OD Then 500 μg OD vs Roflumilast 500 μg OD · Regression, Logistic · p = 0.001 (Study treatment, country and baseline forced expiratory volume in the first second (FEV1) as explanatory variables.) · Odds ratio (or): 0.63 · 95% CI 0.47 to 0.83
  • Roflumilast 500 μg EOD Then 500 μg OD vs Roflumilast 500 μg OD · Regression, Logistic · p = 0.091 (Study treatment, country and baseline forced expiratory volume in the first second (FEV1) as explanatory variables.) · Odds ratio (or): 0.78 · 95% CI 0.59 to 1.04
SecondaryChange From Baseline (V0DT) in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) to Final Visit of the Down-Titration Period

FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication A positive change from Baseline indicates improvement.

Time frame:
Baseline (V0DT) [assessment at end of main period] and Final Visit of Down-Titration Period (Up to Day 56)
Reported as:
Mean · Liters
Change From Baseline (V0DT) in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) to Final Visit of the Down-Titration Period
LitersRoflumilast 250 μg OD Then 500 μg OD_Down Titration PeriodRoflumilast 500 μg EOD_Down-Titration PeriodRoflumilast 500 μg OD_Down Titration Period
Change From Baseline (V0DT) in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) to Final Visit of the Down-Titration Period0.030 ± 0.22940.055 ± 0.41700.007 ± 0.3555
SecondaryPercentage of Participants Prematurely Discontinuing Study Treatment Due to Any Reason During Down-Titration Period
Time frame:
Baseline DT (Day 1 of Down-Titration Period) to Week 8 (Down-Titration Period)
Reported as:
Number · percentage of participants
Percentage of Participants Prematurely Discontinuing Study Treatment Due to Any Reason During Down-Titration Period
percentage of participantsRoflumilast 250 μg OD Then 500 μg OD_Down Titration PeriodRoflumilast 500 μg EOD_Down-Titration PeriodRoflumilast 500 μg OD_Down Titration Period
Percentage of Participants Prematurely Discontinuing Study Treatment Due to Any Reason During Down-Titration Period25.928.218.4
SecondaryChange From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) During the Down-Titration Period

FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.

Time frame:
Baseline DT (Day 1 of Down-Titration Period) to Days 14, 28 and 56 (Down-Titration Period)
Reported as:
Mean · Liters
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) During the Down-Titration Period
LitersRoflumilast 250 μg OD Then 500 μg OD_Down Titration PeriodRoflumilast 500 μg EOD_Down-Titration PeriodRoflumilast 500 μg OD_Down Titration Period
Day 14 (n=20, 32, 34)0.128 ± 0.37080.223 ± 0.41010.097 ± 0.2532
Day 28 (n=20, 29, 31)0.162 ± 0.42740.218 ± 0.44430.070 ± 0.2067
Day 56 (n=26, 39, 38)0.162 ± 0.33110.261 ± 0.46160.127 ± 0.3334
SecondaryChange From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) During the Main Period

FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.

Time frame:
Baseline (Day 1 of Main Period) to Days 15, 29, 57 and 84 (Main Period)
Reported as:
Mean · Liters
Change From Baseline in Pre-bronchodilator Forced Expiratory Volume in First Second (FEV1) During the Main Period
LitersRoflumilast 250 μg OD Then 500 μg ODRoflumilast 500 μg EOD Then 500 μg ODRoflumilast 500 μg OD
Day 15 (n=409, 406, 386)0.067 ± 0.22990.094 ± 0.25730.094 ± 0.2566
Day 29 (n=402, 389, 365)0.099 ± 0.26050.115 ± 0.26290.116 ± 0.2440
Day 57 (n=376, 367, 352)0.104 ± 0.26590.161 ± 0.27650.133 ± 0.2705
Day 84 (n=402, 411, 409)0.117 ± 0.26900.141 ± 0.28820.122 ± 0.2705
SecondaryChange From Baseline in Pre-bronchodilator Forced Vital Capacity (FVC) During the Main Period

Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.

Time frame:
Baseline (Day 1 of Main Period) to Days 15, 29, 57 and 84 (Main Period)
Reported as:
Mean · Liters
Change From Baseline in Pre-bronchodilator Forced Vital Capacity (FVC) During the Main Period
LitersRoflumilast 250 μg OD Then 500 μg ODRoflumilast 500 μg EOD Then 500 μg ODRoflumilast 500 μg OD
Day 15 (n=409, 406, 386)0.096 ± 0.40530.112 ± 0.41680.104 ± 0.4166
Day 29 (n=402, 389, 365)0.139 ± 0.38260.143 ± 0.41720.149 ± 0.4173
Day 57 (n=376, 367, 352)0.156 ± 0.43460.194 ± 0.49740.162 ± 0.4341
Day 84 (n=402, 411, 409)0.157 ± 0.47460.207 ± 0.49250.147 ± 0.4555
SecondaryChange From Baseline in Pre-bronchodilator Forced Vital Capacity (FVC) During the Down-Titration Period

Forced vital capacity is the amount of air which can be forcibly exhaled from the lungs after taking the deepest breath possible. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.

Time frame:
Baseline DT (Day 1 of Down-Titration Period) to Days 14, 28 and 56 (Down-Titration Period)
Reported as:
Mean · Liters
Change From Baseline in Pre-bronchodilator Forced Vital Capacity (FVC) During the Down-Titration Period
LitersRoflumilast 250 μg OD Then 500 μg OD_Down Titration PeriodRoflumilast 500 μg EOD_Down-Titration PeriodRoflumilast 500 μg OD_Down Titration Period
Day 14 (n=20, 32, 34)0.087 ± 0.53920.303 ± 0.51030.104 ± 0.4568
Day 28 (n=20, 29, 31)0.125 ± 0.61510.191 ± 0.47800.067 ± 0.3522
Day 56 (n=26, 39, 38)0.167 ± 0.54920.113 ± 0.51000.029 ± 0.4628
SecondaryChange From Baseline in Treatment Satisfaction Scores During the Main Period

Participants will be asked to assess their satisfaction with their COPD therapy at each visit. The participants will rate their treatment satisfaction on a 7-point scale where 0=very satisfied, 1=satisfied, 2=somewhat satisfied, 3=neither satisfied nor dissatisfied, 4=somewhat dissatisfied, 5=dissatisfied and 6=very dissatisfied. A negative change from Baseline indicates improvement.

Time frame:
Baseline (Day 1 of Main Period) to Days 15, 29, 57 and 84 (Main Period)
Reported as:
Mean · score on a scale
Change From Baseline in Treatment Satisfaction Scores During the Main Period
score on a scaleRoflumilast 250 μg OD Then 500 μg ODRoflumilast 500 μg EOD Then 500 μg ODRoflumilast 500 μg OD
Day 15 (n=410, 408, 386)-0.4 ± 1.12-0.3 ± 1.15-0.3 ± 1.07
Day 29 (n=403, 390, 366)-0.5 ± 1.23-0.5 ± 1.16-0.5 ± 1.22
Day 57 (n=375, 369, 351)-0.6 ± 1.24-0.6 ± 1.26-0.5 ± 1.29
Day 84 (n=407, 416, 412)-0.5 ± 1.43-0.5 ± 1.51-0.3 ± 1.52
SecondaryChange From Baseline in Treatment Satisfaction Scores During the Down-Titration Period

Participants will be asked to assess their satisfaction with their COPD therapy at each visit. The participants will rate their treatment satisfaction on a 7-point scale where 0=very satisfied, 1=satisfied, 2=somewhat satisfied, 3=neither satisfied nor dissatisfied, 4=somewhat dissatisfied, 5=dissatisfied and 6=very dissatisfied. A negative change from Baseline indicates improvement.

Time frame:
Baseline DT (Day 1 of Down-Titration Period) to Days 14, 28 and 56 (Down-Titration Period)
Reported as:
Mean · score on a scale
Change From Baseline in Treatment Satisfaction Scores During the Down-Titration Period
score on a scaleRoflumilast 250 μg OD Then 500 μg OD_Down Titration PeriodRoflumilast 500 μg EOD_Down-Titration PeriodRoflumilast 500 μg OD_Down Titration Period
Day 14 (n=20, 32, 34)-1.1 ± 1.85-0.8 ± 1.57-0.8 ± 1.84
Day 28 (n=20, 29, 31)-1.2 ± 2.01-0.8 ± 1.75-0.9 ± 1.81
Day 56 (n=26, 39, 38)-0.8 ± 2.23-0.3 ± 2.15-0.4 ± 2.26
SecondaryPopulation PK Model Point Estimate for Absorption Rate Constant (Ka) of Roflumilast and Roflumilast N-oxide

PK model point estimates for Ka are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.

Time frame:
Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours at weeks 2 or 8
Reported as:
Number · units per hour (1/h)
Population PK Model Point Estimate for Absorption Rate Constant (Ka) of Roflumilast and Roflumilast N-oxide
units per hour (1/h)All PK Participants_RoflumilastAll PK Participants_Roflumilast N-oxide
Weight=33.5 kg0.900.57
Weight=70 kg0.900.57
Weight=160 kg0.900.57
Age=400.900.57
Age=600.900.57
Age=920.900.57
Smoking=former0.900.57
Smoking=current0.900.57
Sex=female0.900.57
Sex=male0.900.57
SecondaryPopulation PK Model Point Estimate for Apparent Oral Clearance (CL/F) of Roflumilast and Roflumilast N-oxide

PK model point estimates for CL/F are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.

Time frame:
Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours at weeks 2 or 8
Reported as:
Number · liters per hour (L/h)
Population PK Model Point Estimate for Apparent Oral Clearance (CL/F) of Roflumilast and Roflumilast N-oxide
liters per hour (L/h)All PK Participants_RoflumilastAll PK Participants_Roflumilast N-oxide
Weight=33.5 kg5.640.73
Weight=70 kg5.640.89
Weight=160 kg5.641.12
Age=407.231.11
Age=605.640.89
Age=924.350.71
Smoking=former5.640.89
Smoking=current6.501.03
Sex=female5.640.89
Sex=male5.640.79
SecondaryPopulation PK Model Point Estimate for Apparent Central Volume (Vc/F) of Roflumilast and Roflumilast N-oxide

PK model point estimates for Vc/F are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.

Time frame:
Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours at weeks 2 or 8
Reported as:
Number · liters (L)
Population PK Model Point Estimate for Apparent Central Volume (Vc/F) of Roflumilast and Roflumilast N-oxide
liters (L)All PK Participants_RoflumilastAll PK Participants_Roflumilast N-oxide
Weight=33.5 kg26.04.5
Weight=70 kg63.911.0
Weight=160 kg175.230.2
Age=4063.911.0
Age=6063.911.0
Age=9263.911.0
Smoking=former63.911.0
Smoking=current63.911.0
Sex=female63.911.0
Sex=male63.911.0
SecondaryPopulation PK Model Point Estimate for Apparent Peripheral Volume (Vp/F) of Roflumilast and Roflumilast N-oxide

PK model point estimates for Vp/F are calculated using all available PK data for all doses of roflumilast combined and are presented for roflumilast and metabolite roflumilast N-oxide. Results are reported for the subgroups defined according to the covariates (weight, age, smoking status and sex) included in the final model.

Time frame:
Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours at weeks 2 or 8
Reported as:
Number · L
Population PK Model Point Estimate for Apparent Peripheral Volume (Vp/F) of Roflumilast and Roflumilast N-oxide
LAll PK Participants_RoflumilastAll PK Participants_Roflumilast N-oxide
Weight=33.5 kg69.65.0
Weight=70 kg171.012.4
Weight=160 kg468.834.0
Age=40171.012.4
Age=60171.012.4
Age=92171.012.4
Smoking=former171.012.4
Smoking=current171.012.4
Sex=female171.012.4
Sex=male171.012.4
SecondaryTotal PDE4 Inhibitory Activity (tPDE4i)

tPDE4i was derived using in-vitro constants for protein binding and biochemical activity (IC50). tPDE4i is reported for a set of reference participants defined according to the covariates included in the final model.

Time frame:
Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours post-dose at Days 15 and 57. Down-titration: Pre-dose and 1,2,3,4,6 hours post-dose at Days 1 and 14 and pre-dose at Days 28 and 56.
Reported as:
Median · unitless
Total PDE4 Inhibitory Activity (tPDE4i)
unitlessRoflumilast 500 μg ODRoflumilast 500 μg EODRoflumilast 250 μg ODRoflumilast 250 µg Down-Titration
Overall1.17 (0.366 to 2.05)0.608 (0.227 to 1.03)0.563 (0.157 to 1.01)0.583 (0.210 to 1.24)
Age < 65 (n=198,187,229,45)1.06 (0.323 to 1.85)0.559 (0.237 to 0.998)0.518 (0.160 to 0.958)0.511 (0.205 to 0.984)
Age ≥ 65 to < 75 (n=146,159,136,39)1.24 (0.550 to 2.08)0.660 (0.177 to 1.04)0.614 (0.138 to 1.10)0.683 (0.207 to 1.23)
Age ≥ 75 (n=48,53,39,17)1.24 (0.318 to 2.31)0.676 (0.188 to 1.12)0.616 (0.195 to 1.01)0.712 (0.300 to 1.32)
Weight < 60 kg (n=56,78,73,17)1.34 (0.591 to 2.64)0.755 (0.258 to 1.22)0.653 (0.156 to 1.12)0.934 (0.325 to 1.39)
Weight ≥ 60 kg (n=336,321,331,84)1.12 (0.339 to 1.99)0.592 (0.223 to 1.01)0.552 (0.158 to 0.971)0.538 (0.202 to 1.02)
Males (n=300,297,290,66)1.12 (0.363 to 1.96)0.585 (0.226 to 0.994)0.558 (0.145 to 0.998)0.575 (0.213 to 1.14)
Females (n=92,102,114,35)1.29 (0.468 to 2.38)0.696 (0.260 to 1.15)0.618 (0.189 to 1.01)0.626 (0.217 to 1.25)
Current Smoker (n=179,183,200,45)1.04 (0.327 to 1.88)0.568 (0.247 to 0.976)0.514 (0.101 to 0.949)0.554 (0.228 to 1.21)
Former Smoker (n=213,216,204,56)1.25 (0.416 to 2.15)0.632 (0.186 to 1.09)0.626 (0.196 to 1.10)0.624 (0.207 to 1.30)
SecondarySummary Statistics of Predicted Total PDE4 Inhibitory Activity (tPDE4i)

tPDE4i was derived using in-vitro constants for protein binding and biochemical activity (IC50). An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have to have a causal relationship with this treatment. A treatment-emergent adverse event (TEAE) is defined as an adverse event with an onset that occurs after receiving study drug. Adverse Events of Interest (AEI) for PK analyses included: headache, diarrhea, nausea, vomiting, abdominal pain, appetite disorders, sleep disorders, angioedema, psychiatric disorders (anxiety, nervousness), psychiatric disorders (depression,suicidal ideation,behaviour) and weight loss.

Time frame:
Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours post-dose at Days 15 and 57. Down-titration: Pre-dose and 1,2,3,4,6 hours post-dose at Days 1 and 14 and pre-dose at Days 28 and 56.
Reported as:
Median · unitless
Summary Statistics of Predicted Total PDE4 Inhibitory Activity (tPDE4i)
unitlessRoflumilast 500 μg ODRoflumilast 250 μg OD
All Participants (n=1114,76)1.17 (0.352 to 2.03)0.611 (0.197 to 1.243)
Discontinuation due to Any AEI=Yes (n=67,62)1.28 (0.427 to 2.22)0.647 (0.201 to 1.239)
Discontinuation due to Any AEI=No (n=1047,14)1.16 (0.339 to 2.02)0.436 (0.212 to 1.069)
Discontinuation due to Any AE=Yes (n=77,64)1.29 (0.464 to 2.10)0.647 (0.204 to 1.237)
Discontinuation due to Any AE=No (n=1037,12)1.16 (0.337 to 2.02)0.408 (0.209 to 1.006)
Discontinuation Due to Any Reason=Yes (n=106,75)1.23 (0.416 to 2.06)0.600 (0.197 to 1.243)
Discontinuation Due to Any Reason=No (n=1008,1)1.16 (0.332 to 2.02)0.626 (0.626 to 0.626)
At Least 1 AEI=Yes (n=536,75)1.23 (0.453 to 2.09)0.600 (0.197 to 1.243)
At Least 1 AEI=No (578,1)1.12 (0.297 to 1.98)0.929 (0.929 to 0.929)
At Least 1 AE=Yes (n=693,76)1.22 (0.416 to 2.07)0.611 (0.197 to 1.243)
At Least 1 AE=No (n=421,0)1.08 (0.294 to 1.97)NA (NA to NA)
SecondaryMedian Simulated Percentage of Participants With Adverse Events of Interest

The PK model predicted the total PDE4 inhibitory activity and the median simulated percentage of participants with Adverse Events of Interest during 12 weeks of treatment based on 1000 participants simulated. Results are reported for the set of reference participants defined according to the covariates \[weight, smoking status, sex, age and long acting muscarinic antagonist (LAMA)\] included in the final model and tPDE4i. Adverse Events of Interest (AEI) for PK analyses included: headache, diarrhea, nausea, vomiting, abdominal pain, appetite disorders, sleep disorders, angioedema, psychiatric disorders (anxiety, nervousness), psychiatric disorders (depression, suicidal ideation, behaviour) and weight loss.

Time frame:
Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours post-dose at Days 15 and 57. AEIs: 12 Weeks
Reported as:
Number · percentage of participants
Median Simulated Percentage of Participants With Adverse Events of Interest
percentage of participantsRoflumilast 250 μg ODRoflumilast 500 μg EODRoflumilast 500 μg OD
Weight=48 kg (tPDE4i=0.72,0.72,1.45)53.2 (0.352 to 2.03)53.2 (0.197 to 1.243)61.8
Weight=74 kg (tPDE4i=0.65,0.65,1.30)52.3 (0.427 to 2.22)52.3 (0.201 to 1.239)60.1
Weight=105 kg (tPDE4i=0.60.0.60,1.19)51.7 (0.339 to 2.02)51.7 (0.212 to 1.069)58.8
Former Smoker (tPDE4i=0.65,0.65,1.30)52.3 (0.464 to 2.10)52.3 (0.204 to 1.237)60.1
Current Smoker (tPDE4i=0.56,0.56,1.13)42.5 (0.337 to 2.02)42.5 (0.209 to 1.006)49.2
Male (tPDE4i=0.65,0.65,1.30)52.3 (0.416 to 2.06)52.3 (0.197 to 1.243)60.1
Female (tPDE4i=0.72,0.72,1.45)53.2 (0.332 to 2.02)53.2 (0.626 to 0.626)61.8
Age=51 (tPDE4i=0.58,0.58,1.15)51.4 (0.453 to 2.09)51.4 (0.197 to 1.243)58.4
Age=64 (tPDE4i=0.65,0.65,1.30)52.3 (0.297 to 1.98)52.3 (0.929 to 0.929)60.1
Age=77 (tPDE4i=0.72,0.72,1.44)53.2 (0.416 to 2.07)53.2 (0.197 to 1.243)61.7
With LAMA (tPDE4i=0.65,0.65,1.30)52.3 (0.294 to 1.97)52.3 (NA to NA)60.1
Without LAMA (tPDE4i=0.65,0.65,1.30)43.543.551.4
SecondaryMedian Simulated Absolute Change From Baseline in FEV1 at Weeks 4 and 12

The PK model predicted the total PDE4 inhibitory activity and the median simulated Change from Baseline (CFB) in FEV1 at Week 4 and the Change from Baseline in FEV1 at Week 12 during 12 weeks of treatment with roflumilast 500 μg OD based on 1000 participants simulated. Results are reported for the set of reference participants defined according to the covariates \[weight, smoking status, sex, age, race, COPD severity, concomitant long acting muscarinic antagonist (LAMA) and Percent FEV1 reversibility\] included in the final model and tPDE4i. FEV1 is the amount of air which can be forcibly exhaled from the lungs in the first second of a forced exhalation. Pulmonary function testing was performed using spirometry prior to taking study medication. A positive change from Baseline indicates improvement.

Time frame:
Main period: Pre-dose and 1,2,3,4,6 hours post-dose or pre-dose and 2 hours post-dose at Days 15 and 57. FEV-1: Pre-dose and Weeks 4 and 12
Reported as:
Number · milliliters (mL)
Median Simulated Absolute Change From Baseline in FEV1 at Weeks 4 and 12
milliliters (mL)Roflumilast 500 μg OD_CFB in FEV1 @ Week 4Roflumilast 500 μg OD_CFB in FEV1 @ Week 12
Weight=33.5 kg (tPDE4i=1.012,1.012)50 (0.197 to 1.243)32
Weight=70 kg (tPDE4i=0.839,0.839)60.5 (0.201 to 1.239)56
Weight=160 kg (tPDE4i=0.681,0.681)108 (0.212 to 1.069)157
Current Smoker (tPDE4i=0.729,0.729)99.5 (0.204 to 1.237)96.5
Former/Never Smoker (tPDE4i=0.839,0.839)60.5 (0.209 to 1.006)56
Male (tPDE4i=0.839,0.839)60.5 (0.197 to 1.243)56
Female (tPDE4i=0.937,0.937)53.2 (0.626 to 0.626)49.8
Age=40 years (tPDE4i=0.675,0.675)57.6 (0.197 to 1.243)52.2
Age=60 years (tPDE4i=0.839,0.839)60.5 (0.929 to 0.929)56
Age=92 years (tPDE4i=1.06,1.06)56.4 (0.197 to 1.243)53.3
Asian (tPDE4i=0.839,0.839)56.1 (NA to NA)52
non-Asian (tPDE4i=0.839,0.839)60.556
COPD_Not Very Severe (tPDE4i=0.839,0.839)60.556
COPD_Very Severe (tPDE4i=0.839,0.839)42.239.1
LAMA=Yes (tPDE4i=0.839,0.839)60.556
LAMA=No (tPDE4i=0.839,0.839)63.558.8
%FEV1 Reversibility=-28% (tPDE4i=0.839,0.839)68.163.1
%FEV1 Reversibility=10% (tPDE4i=0.839,0.839)60.556
%FEV1 Reversibility=147% (tPDE4i=0.839,0.839)32.930.5

Adverse events

Collected over Main Treatment Period: First dose of study drug to 30 days past last dose or first dose in the Down-Titration Period (Up to 114 Days). Down-Titration Period: First dose of study drug to 30 days past the last dose of study drug (Up to 86 Days).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roflumilast 250 μg OD Then 500 μg OD_Main Treatment Period—19/441 (4.3%)239/441 (54.2%)
Roflumilast 500 μg EOD Then 500 μg OD_Main Treatment Period—22/437 (5%)248/437 (56.8%)
Roflumilast 500 μg OD_Main Treatment Period—20/443 (4.5%)272/443 (61.4%)
Roflumilast 250 μg OD Then 500 μg OD_Down Titration Period—1/27 (3.7%)13/27 (48.1%)
Roflumilast 500 μg EOD_Down-Titration Period—0/39 (0%)21/39 (53.8%)
Roflumilast 500 μg OD_Down Titration Period—0/38 (0%)25/38 (65.8%)
Most frequent serious events
Showing 10 of 39
Most frequent serious events
EventRoflumilast 250 μg OD Then 500 μg OD_Main Treatment PeriodRoflumilast 500 μg EOD Then 500 μg OD_Main Treatment PeriodRoflumilast 500 μg OD_Main Treatment PeriodRoflumilast 250 μg OD Then 500 μg OD_Down Titration PeriodRoflumilast 500 μg EOD_Down-Titration PeriodRoflumilast 500 μg OD_Down Titration Period
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders8/44113/4377/4431/270/390/38
DyspnoeaRespiratory, thoracic and mediastinal disorders3/4410/4373/4430/270/390/38
PneumoniaInfections and infestations2/4411/4371/4430/270/390/38
Myocardial ischaemiaCardiac disorders0/4411/4371/4430/270/390/38
Atrial fibrillationCardiac disorders0/4411/4370/4430/270/390/38
Acute sinusitisInfections and infestations0/4411/4370/4430/270/390/38
Respiratory tract infectionInfections and infestations0/4411/4370/4430/270/390/38
Upper respiratory tract infectionInfections and infestations0/4411/4370/4430/270/390/38
Lower limb fractureInjury, poisoning and procedural complications0/4411/4370/4430/270/390/38
Spinal osteoarthritisMusculoskeletal and connective tissue disorders0/4411/4370/4430/270/390/38
Most frequent other events
Showing 10 of 34
Most frequent other events
EventRoflumilast 250 μg OD Then 500 μg OD_Main Treatment PeriodRoflumilast 500 μg EOD Then 500 μg OD_Main Treatment PeriodRoflumilast 500 μg OD_Main Treatment PeriodRoflumilast 250 μg OD Then 500 μg OD_Down Titration PeriodRoflumilast 500 μg EOD_Down-Titration PeriodRoflumilast 500 μg OD_Down Titration Period
DiarrhoeaGastrointestinal disorders107/441113/437134/4433/276/3911/38
Decreased appetiteMetabolism and nutrition disorders100/441105/437129/4433/278/399/38
HeadacheNervous system disorders107/441115/437115/4432/277/3910/38
InsomniaPsychiatric disorders97/441100/437106/4432/2710/396/38
NauseaGastrointestinal disorders87/44192/437110/4431/275/398/38
Abdominal painGastrointestinal disorders69/44158/43764/4430/276/395/38
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders34/44139/43738/4433/273/391/38
Abdominal pain upperGastrointestinal disorders19/44115/43727/4430/273/393/38
NasopharyngitisInfections and infestations7/44111/43712/4430/270/393/38
TremorNervous system disorders0/4410/4370/4432/271/390/38

Baseline characteristics

Safety Analysis Set (SAS) included all randomized participants who took at least one dose of study medication. Main Treatment Period.

Age, Continuous
Age, Continuous(years)Roflumilast 250 μg OD Then 500 μg ODRoflumilast 500 μg EOD Then 500 μg ODRoflumilast 500 μg ODTotal
Mean64.2 ± 7.8165.0 ± 8.2164.6 ± 8.3664.6 ± 8.13
Age, Customized
Age, Customized(participants)Roflumilast 250 μg OD Then 500 μg ODRoflumilast 500 μg EOD Then 500 μg ODRoflumilast 500 μg ODTotal
40-64 years242202224668
65-84 years199235217651
85 years and over0022
Sex: Female, Male
Sex: Female, Male(Participants)Roflumilast 250 μg OD Then 500 μg ODRoflumilast 500 μg EOD Then 500 μg ODRoflumilast 500 μg ODTotal
Female121112105338
Male320325338983
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Roflumilast 250 μg OD Then 500 μg ODRoflumilast 500 μg EOD Then 500 μg ODRoflumilast 500 μg ODTotal
Hispanic or Latino1258
Not Hispanic or Latino4284234261277
Missing12121236
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Roflumilast 250 μg OD Then 500 μg ODRoflumilast 500 μg EOD Then 500 μg ODRoflumilast 500 μg ODTotal
American Indian or Alaskan Native0101
Asian32303294
Black or African American3339
Native Hawaiian/Other Pacific Islander1438
White4053994051209
Region of Enrollment
Region of Enrollment(participants)Roflumilast 250 μg OD Then 500 μg ODRoflumilast 500 μg EOD Then 500 μg ODRoflumilast 500 μg ODTotal
Bulgaria36183084
Germany12241652
Greece86620
Hungary827479235
Korea, Republic Of22111346
Philippines7131030
Poland606871199
Romania544644144
Russia374855140
Slovakia403827105
South Africa17182661
Spain2215
Thailand26917
Ukraine565854168
United Kingdom67215
Height
Height(cm)Roflumilast 250 μg OD Then 500 μg ODRoflumilast 500 μg EOD Then 500 μg ODRoflumilast 500 μg ODTotal
Mean169.1 ± 8.73168.8 ± 8.66169.1 ± 8.55169.0 ± 8.64
Weight
Weight(kg)Roflumilast 250 μg OD Then 500 μg ODRoflumilast 500 μg EOD Then 500 μg ODRoflumilast 500 μg ODTotal
Mean75.59 ± 18.62774.31 ± 17.80875.68 ± 16.94975.20 ± 17.804

5 further baseline measures are reported on the registry.

08

Study locations

2 sites
  • Bardejov, Slovakia
  • Spisska Nova Ves, Slovakia
09

References and documents

Publications

  • Facius A, Marostica E, Gardiner P, Watz H, Lahu G. Pharmacokinetic and Pharmacodynamic Modelling to Characterize the Tolerability of Alternative Up-Titration Regimens of Roflumilast in Patients with Chronic Obstructive Pulmonary Disease. Clin Pharmacokinet. 2018 Aug;57(8):1029-1038. doi: 10.1007/s40262-018-0671-4. PubMed 29797235 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2014 to primary completion in Sep 2015, 16 months.

Results were first posted in Mar 2017, 1 year 6 months after primary completion.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 16 months is below that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2014
First posted
Jun 18, 2014
StartActual
May 1, 2014
Primary completionActual
Sep 1, 2015
CompletionActual
Sep 1, 2015
Results first posted
Mar 14, 2017
Last update
Apr 20, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02165826
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jun 18, 2014
Start date
May 1, 2014
Primary completion
Sep 1, 2015
Completion
Sep 1, 2015
Results posted
Mar 14, 2017
Last update
Apr 20, 2017

Study contacts

AstraZeneca AstraZeneca
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roflumilast

Start the discussion